ReviewFuture medicinal chemistry2025
Advances in antitumor effects of pterostilbene and its derivatives.
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Natural Products in Cancer Research: Mechanistic Advances, Translational Challenges, and the Emerging Role of Chilean Biodiversity.Molecules (Basel, Switzerland) · 2026Review
- Pterostilbene (grape flavonoid) mitigates gastric ulcer events in vivo: biochemical and histopathological approaches.Journal of molecular histology · 2025Article
- Pterostilbene Induces Apoptosis in Awakening Quiescent Prostate Cancer Cells by Upregulating C/EBP-β-Mediated SOD2 Transcription.International journal of biological sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pterostilbene (PT) is a naturally occurring small molecule stilbenoid that has garnered significant attention due to its potential therapeutic effects in tumor diseases. In this review, we conducted a comprehensive analysis of the antitumor effects of PT and its derivatives on various cancer types, including colon, breast, liver, lung, and pancreatic cancers in recent 20 years. We have succinctly summarized the PT derivatives that exhibit superior anti-tumor efficacy compared to PT. Additionally, we reviewed the potential structure-activity relationship (SAR) rules and clinical application methods to establish a foundation for chemical modification and clinical utilization of stilbene compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.